ARHGEF12 and leishmaniasis: In summary, we present a novel biosynthetic approach that increases the possibility of producing L-ARG inhibitors via engineered E. coli and opens the possibility of exploring unnatural substrates to produce new compounds with the clinical potential to treat leishmaniasis.